Gå till innehåll

Kommersiellt obunden läkemedelsinformation riktad till läkare och sjukvårdspersonal

Denosumab

Summary

Risk. The use of amino acids, proteins and peptides is not considered to have any environmental impact.

 

This information comes from Fass.

Detailed information

Fass environmental information

Fass environmental information for Prolia (denosumab) from Amgen (downloaded 2019-08-19).

Risk

The use of amino acids, proteins and peptides is not considered to have any environmental impact.

According to the European Medicines Agency guideline on environmental risk assessments for pharmaceuticals (EMA/CHMP/SWP/4447/00) vitamins, electrolytes, amino acids, peptides, proteins, carbohydrates, lipids proteins, vaccines and herbal medicinal products are exempted because they are unlikely to result in significant risk to the environment.

References

  1. Fass för vårdpersonal.
  2. European Medicines Agency, EMA: Committee for Medicinal Products for Human Use (CHMP). Guideline on the Environmental Risk Assessment of Medicinal Products for Human Use. 1 June 2006.

Author: Health and Medical Care Administration, Region Stockholm